Vivek Garipalli - Jan 7, 2022 Form 4 Insider Report for CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV)

Role: Chief Executive Officer, Director, 10%+ Owner
Signature: /s/ Gia Lee, as Attorney-in-Fact
Stock symbol: CLOV
Transactions as of: Jan 7, 2022
Transactions value $: -$5,260,847
Form type: 4
Date filed: 1/11/2022, 08:51 PM
Next filing: Apr 28, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CLOV	Class B Common Stock	Options Exercise		+3.34M			3.34M	Jan 7, 2022	Direct	F1
transaction	CLOV	Class B Common Stock	Tax liability	-$5.26M	-1.66M	-49.8%	$3.16	1.68M	Jan 7, 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CLOV	Restricted Stock Unit	Options Exercise	$0	-3.34M	-20%	$0.00	13.4M	Jan 7, 2022	Class B Common Stock	3.34M		Direct	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class B Common Stock upon settlement for no consideration.
F2	On January 7, 2021, the Reporting Person was granted 16,713,491 RSUs, vesting in equal annual installments over five years, beginning on January 7, 2022, subject to the continuous service of the Reporting Person as CEO, Co-CEO or Executive Chairman of the Issuer through each vesting date. Shares of the Issuer's Class B common stock will be delivered to the Reporting Person upon vesting.
F3	The Class B Common Stock will be convertible into shares of Class A Common Stock on a one-to-one basis at the option of the holders of the Class B Common Stock at any time upon written notice to the Issuer.